MARKET NEWS

Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the US
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers
Amydis Receives NIH Grant Award to Develop a Novel TDP-43 Retinal Tracer in Patients With ALS & FTD
AUM Biosciences Receives FDA Orphan Drug Designation for the Treatment of Solid Tumors With the NTRK Fusion Gene
Gerresheimer & Zollner Enter Strategic Partnership 
Blue Water Vaccines Announces Exploration of its VLP Platform for Use in Monkeypox Vaccine Candidate

  FEATURED EDITORIAL

 

  COMPANY PROFILE

For over 30 years, DDL has provided extraordinary service and specialized testing expertise to the medical device and pharmaceutical industries. Our reliable quality, responsive attention, and on-schedule completion for packaging, medical device, and combination products testing secures confidence in performance and safety while achieving regulatory compliance. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Lonza Strengthens Micronization Portfolio With the Introduction of X-Ray Powder Diffraction Capability

Lonza Strengthens Micronization Portfolio With the Introduction of X-Ray Powder Diffraction Capability

Lonza has expanded the range of particle engineering services offered by its Monteggio (CH) site through the introduction of X-ray powder diffraction (XRPD). This rapid analytical technique provides additional….

Agios Announces Publication of Phase 3 ACTIVATE-T Data Demonstrating Benefits of PYRUKYND for Adults With Pyruvate Kinase Deficiency

Agios Announces Publication of Phase 3 ACTIVATE-T Data Demonstrating Benefits of PYRUKYND for Adults With Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. recently announced data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular….

Kapruvia Approved in Switzerland With Additional Regulatory Decisions Expected in H2 2022

Kapruvia Approved in Switzerland With Additional Regulatory Decisions Expected in H2 2022

Cara Therapeutics, Inc. and Vifor Fresenius Medical Care Renal Pharma recently announced they have received approval for Kapruvia from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia will be the first….

Gerresheimer Invests Up to  Million in US Production Facility

Gerresheimer Invests Up to $94 Million in US Production Facility

Gerresheimer AG recently announced investments to rapidly expand its manufacturing, supply, and logistics capability for glass vials in the US. The project will be supported by the Biomedical Advanced Research….

  WHITEPAPERS & WEBINARS

WEBINAR - Getting to the Core of Pellet Coating

WEBINAR - Getting to the Core of Pellet Coating

This webinar is part of The future of solid dosage, an ACG 360 webinar series covering wide-ranging, simple, and transformative ways to achieve smarter pharma formulation, manufacture, and packaging.

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

WHITEPAPER - Antibody-Based Drug Discovery at the Speed of Light

Capabilities and technology combine to provide First-to-Human antibody discovery, development and clinical manufacturing. Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics.

Download our whitepaper and learn …

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

WHITEPAPER - Protecting Workers and the Environment: Facilities and Processes Key to Safely Making Highly Potent Drug Products

Highly potent APIs (HPAPI) are rapidly growing in the pharmaceutical industry. Manufacturing solid oral dosage forms (SOD) containing HPAPIs requires specific knowledge, skills, and precision without compromising environmental or worker safety.

Enteris BioPharma’s HPAPI manufacturing facility was custom-built with comprehensive …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 31 – Injection Devices
September 7 – Lyophilization Manufacturing